Lipoprotein (a) as a treatment target for cardiovascular disease prevention and related therapeutic strategies: a critical overview. (14th August 2021)

• Record Type: Journal Article
• Authors: Parthymos, Ioannis; Kostapanos, Michael S; Mikhailidis, Dimitri P; Florentin, Matilda
• Is Part Of: European journal of preventive cardiology. Volume 29:Number 5(2022)
• Page Start: 739
• Page End: 755
• Publication Date: 2021-08-14
• Subjects: Lipoprotein(a) -- Cardiovascular disease -- Aortic stenosis -- Proprotein convertase subtilisin/kexin type 9 inhibitors -- Antisense oligonucleotides; Cardiovascular system -- Diseases -- Prevention -- Periodicals; Cardiac patients -- Rehabilitation -- Periodicals; 616.12
• DOI: 10.1093/eurjpc/zwab052
• Languages: English
• ISSNs: 2047-4873

Abstract

Abstract: Advances in several fields of cardiovascular (CV) medicine have produced new treatments (e.g. to treat dyslipidaemia) that have proven efficacy in terms of reducing deaths and providing a better quality of life. However, the burden of CV disease (CVD) remains high. Thus, there is a need to search for new treatment targets. Lipoprotein (a) [Lp(a)] has emerged as a potential novel target since there is evidence that it contributes to CVD events. In this narrative review, we present the current evidence of the potential causal relationship between Lp(a) and CVD and discuss the likely magnitude of Lp(a) lowering required to produce a clinical benefit. We also consider current and investigational treatments targeting Lp(a), along with the potential cost of these interventions.